Oligonucleotides

Sumitomo Chemical has commissioned a new cGMP commercial-scale small molecules plant at its Oita site, adding new capacity to meet the growing demand of its global customer base, now offering more than 1,000m3 reactor capacity over 4 cGMP sites, guaranteeing security of supply for its new projects.   A brand-new state-of-the-art cGMP pilot plant will be opened in Osaka in fall for quick supply of the first GMP batches.

 

Sumitomo Chemical provides high-quality oligonucleotides as drug substance for nucleic acid drugs to various customers.
We offer an agile response to your nucleic acid drug discovery and development, based on the same trust and proven technology that we have cultivated in the manufacture of small-molecule API for more than 40 years.